The U.S. Food and Drug Administration issued a warning letter to Chara Biologics, Inc., a company marketing stem cell and exosome-based therapies for conditions including arthritis, neurological disorders, and autoimmune diseases.
The warning cited four categories of violation:
- Marketing unapproved new drugs
- Failure to meet FDA biologics regulations
- cGMP (current good manufacturing practice) violations
- Misbranding of biological products
What Chara Biologics Was Selling
According to the FDA’s letter, three products were marketed without approval:
- CharaExo — amniotic fluid-derived exosomes
- CharaCore — umbilical cord-derived cellular therapy
- CharaOmni — stem cell-based skincare product
Key violations noted by the FDA
Unapproved new drugs and biologics. The products were marketed as treatments for serious conditions including Alzheimer’s, Parkinson’s, autism, and autoimmune disease — without FDA approval. Any cell-based therapy that does not meet minimal manipulation standards must undergo clinical trials and obtain a Biologics License Application (BLA) before legal marketing.
cGMP violations. Chara Biologics failed to establish quality controls for product safety, consistency, and sterility. Donor screening procedures were not validated, raising concerns about transmission of infectious disease.
Misbranding and false advertising. The company extended product expiration dates without supporting stability data — misbranding under the FD&C Act. Promotional materials made unsupported claims about exosome efficacy for infertility, kidney disease, and wound healing.
The FDA’s Regulatory Framework
The FDA regulates regenerative medicine products under two legal frameworks:
- 21 CFR 1271 for minimally manipulated human cells, tissues, and tissue-based products (HCT/Ps)
- Section 351 of the Public Health Service Act for biological drugs requiring FDA approval
Stem cell therapies: FDA oversight
| Category | Regulatory status |
|---|---|
| Autologous stem cells (from the patient’s own body) | May qualify under Section 361 if minimally manipulated |
| Allogeneic stem cells (from donors) | Typically require BLA approval under Section 351 |
| Expanded stem cells (lab-grown) | Must be tested in clinical trials before use |
Exosome therapy
Exosomes — small vesicles released by stem cells — are gaining traction in regenerative medicine, but no exosome product is currently FDA-approved for clinical use.
Risks and challenges:
- Quality control. Source and handling of exosomes affect safety; poorly processed exosomes can carry contaminants or inactive signaling molecules.
- No standardized dosing. Unlike pharmaceuticals, exosome therapy lacks consistent formulations.
- Immune reactions. Certain formulations have been associated with adverse responses.
What Patients Should Verify
Patients seeking exosome treatment — for microneedling, hair loss, or joint pain — should verify:
- The provider’s credentials
- The source of the exosomes (FDA-compliant labs?)
- Whether the product is tested for purity and potency
- Whether the provider uses imaging guidance for injections
Insurance Coverage and Patient Access
A persistent disparity: most insurance providers will pay for invasive surgeries such as joint replacements but will not cover PRP, stem cell, or exosome therapy — even when these treatments may be less expensive long-term, carry fewer complications, and prevent the need for major surgery.
Reasons for the disparity:
- Surgery has decades of clinical data and is FDA-approved.
- The insurance model favors procedural medicine (high-cost, high-reimbursement surgeries).
- Pharmaceutical companies have more influence in healthcare policy than regenerative medicine developers.
What Happens Next for Chara Biologics
Chara Biologics must cease marketing the unapproved products, comply with FDA manufacturing standards, and either file a BLA or apply for an Investigational New Drug (IND) authorization to legally market in the U.S.
The FDA’s action signals a stronger regulatory stance on unapproved stem cell and exosome treatments. The future of these therapies depends on scientific validation, regulatory compliance, and responsible marketing.
For Patients Considering These Therapies
- Verify regulatory compliance — ask whether the treatment meets FDA or EMA standards.
- Seek reputable providers with imaging guidance and high-quality biologics.
- Be wary of cure-all marketing language.